In one paragraphArticle in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Daniel K NomahCentre Estudis Epidemiològics Sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Department de Salut, Generalitat de Catalunya, 08916 Badalona, Spain.ORCID 0000-0002-3988-9316 Alba G RoblesInfectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Andreu BrugueraCentre Estudis Epidemiològics Sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Department de Salut, Generalitat de Catalunya, 08916 Badalona, Spain.ORCID 0000-0002-7524-0768 Juan M TiraboschiHIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, 08907 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-0073-873X Susana BenetFundació Lluita Contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.
Javier García-PérezAIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-7551-7803 Paloma JimenezAIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, 28029 Madrid, Spain.
Gemma NavarroUnidad de Epidemiologia, Parc Tauli Hospital Universitari, Institut d'Investigaciói i Innovació Parc Taulí (I3PT-Cerca), Universitat Autònoma de Barcelona, 08208 Sabadell, Spain.
Sonsoles Sánchez-PalominoHIV/AIDS Unit, Infectious Diseases Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-9142-812X Paula SuanzesInfectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0002-6871-0098 Mercedes Garcia-GasallaCentro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0002-9842-6768 Francisco HomarInternal Medicine Department, Son Llatzer University Hospital, 07198 Palma, Spain.
Beatriz MotheFundació Lluita Contra les Infeccions, Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain.ORCID 0000-0001-9975-407X Jordi CasabonaCentre Estudis Epidemiològics Sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Department de Salut, Generalitat de Catalunya, 08916 Badalona, Spain.
Juliana Reyes-UrueñaCentre Estudis Epidemiològics Sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Department de Salut, Generalitat de Catalunya, 08916 Badalona, Spain.ORCID 0000-0002-3122-6518 María J BuzónInfectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.ORCID 0000-0003-4427-9413 Jose M MiroHIV/AIDS Unit, Infectious Diseases Service, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-8057-7755 The Covihvac Study Group
Funding
Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer 80:20Gilead Sciences (Spain) GLD21/00052Instituto de Salud Carlos III CPII22/00005Ministerio de Ciencia, Innovación y Universidades PID2021-123321OB-I00
6 · The paper itselfAbstract
People with HIV (PWH) may exhibit altered immune responses to SARS-CoV-2 vaccination due to persistent immune dysregulation despite antiretroviral therapy. We evaluated humoral immunogenicity following mRNA SARS-CoV-2 vaccination in PWH according to CD4 T-cell count and compared responses with HIV-negative controls. The study included 57 PWH stratified by CD4 count (<200 and ≥200 cells/µL), alongside 12 HIV-negative controls. Neutralizing antibody titers (NT50) against SARS-CoV-2 pseudoviruses expressing the D614G and Omicron BA.5 spike variants were measured using a luciferase-based neutralization assay one month (M1) and six months (M6) after primary vaccination with BNT162b2 or mRNA-1273. PWH with CD4 counts ≥ 200 cells/µL demonstrated higher neutralizing titers against D614G at M1 and M6, with significant differences observed between CD4 groups (M1:
Indexed as
COVID-19HIVhumoral responseSARS-CoV-2vaccination
Identifiers
PMID42075289
PMCPMC13119501
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390